Alpha-synuclein pathology represents one of the most critical and intensively studied mechanisms in modern neuroscience, constituting a hallmark of several neurodegenerative diseases collectively termed synucleinopathies[1]. These disorders include Parkinson's disease (PD), dementia with Lewy bodies (DLB), multiple system atrophy (MSA), pure autonomic failure (PAF), and the recently described东亚型阿尔茨海默病 variant known as brainstem predominant alpha-synucleinopathy[2]. The abnormal accumulation, aggregation, and deposition of the protein alpha-synuclein (α-syn) within the central and peripheral nervous systems represents one of the most prevalent protein misfolding diseases in human neurology, affecting millions of individuals worldwide[3].
The significance of α-syn in neurodegeneration was first recognized with the identification of Lewy bodies—intracytoplasmic inclusions composed of aggregated α-syn—in the substantia nigra of patients with Parkinson's disease over a century ago[4]. However, it was not until the 1990s that α-syn was identified as the major constituent of these pathological inclusions, revolutionizing our understanding of neurodegenerative proteinopathies[5]. Subsequent discoveries establishing links between SNCA gene mutations and familial Parkinson's disease further cemented the central role of this protein in disease pathogenesis[6].
Understanding the biology of α-syn, from its normal physiological functions to its pathological transformations, is essential for developing disease-modifying therapies for these devastating disorders. The complex interplay between genetic susceptibility, environmental factors, and age-related changes in protein homeostasis creates a permissive environment for α-syn misfolding and aggregation. This article provides a comprehensive overview of current knowledge regarding α-syn pathology, spanning molecular mechanisms, clinical correlations, therapeutic strategies, and biomarker development.
In the healthy brain, α-syn performs several important physiological functions that are essential for neuronal health and function[7]. The protein is highly enriched in presynaptic terminals, where it constitutes approximately 1% of total cytosolic protein, reflecting its importance in synaptic physiology[8]. This presynaptic localization, combined with its ability to bind synaptic vesicles, suggests critical roles in modulating neurotransmitter release and synaptic plasticity[9].
Synaptic Vesicle Regulation: α-syn plays critical roles in synaptic vesicle pool maintenance, neurotransmitter release, and synaptic plasticity[10]. Through interactions with synaptic vesicles, α-syn modulates vesicle clustering, release probability, and the dynamics of synaptic vesicle cycling[11]. The protein facilitates the recycling of synaptic vesicles by promoting the formation of synaptic vesicle clusters and regulating the availability of vesicles for release during neurotransmission[12]. Studies in knockout mice have demonstrated that loss of α-syn leads to deficits in synaptic transmission, although these effects are often subtle and compensated by other synuclein family members[13].
Dopamine Biosynthesis: α-syn interacts with tyrosine hydroxylase (TH) and affects dopamine biosynthesis[14]. The protein can inhibit TH activity, the rate-limiting enzyme in catecholamine synthesis, suggesting a regulatory role in dopaminergic neurotransmission[15]. This interaction is particularly relevant given the selective vulnerability of dopaminergic neurons in Parkinson's disease. Additionally, α-syn may modulate dopamine storage by interacting with the vesicular monoamine transporter 2 (VMAT2), thereby regulating the packaging of dopamine into synaptic vesicles[16].
Cellular Homeostasis: α-syn participates in various cellular homeostatic processes that are essential for neuronal survival[17]:
Chaperone Activity: The N-terminal region of α-syn exhibits molecular chaperone-like activity, potentially protecting against cellular stress[23]. This function may be relevant to its aggregation in disease states, as the chaperone activity may be overwhelmed or diverted during pathological processes. The protein can protect against mitochondrial dysfunction and oxidative stress, suggesting a neuroprotective role under normal physiological conditions[24].
The α-syn protein contains three distinct domains with different structural propensities that contribute to its unique biophysical properties and disease-related aggregation potential[25]:
N-Terminal Domain (Residues 1-60): This region contains seven imperfect repeats of the motif KTKEGV, which form amphipathic α-helices upon membrane binding[26]. This domain mediates interactions with lipid membranes, particularly synaptic vesicles, and is the site of pathogenic mutations associated with familial PD including A53T, A30P, E46K, and H50Q[27]. The lipid-binding capacity of this domain is thought to be important for the protein's normal physiological function at presynaptic terminals, while mutations in this region can enhance or reduce membrane binding with implications for aggregation propensity[28].
NAC Domain (Residues 61-95): The non-Aβ component (NAC) domain is hydrophobic and central to the aggregation process[29]. This region contains the sequence "VQIVYK" (residues 71-77), which forms the core of β-sheet structures in fibrils[30]. Deletion of this region prevents aggregation, highlighting its essential role in pathology[31]. The NAC domain is unique to α-syn among the synuclein family and is absent in beta-synuclein and gamma-synuclein, which may explain why these related proteins do not form fibrillar aggregates under normal conditions[32].
C-Terminal Domain (Residues 96-140): The acidic C-terminal tail is natively disordered and interacts with metal ions (Ca²⁺, Cu²⁺) and other proteins[33]. This domain has chaperone activity and may regulate aggregation by interacting with the NAC domain through intramolecular interactions[34]. The C-terminal tail also contains multiple sites for post-translational modifications, including phosphorylation, ubiquitination, and nitration, which can modulate the protein's aggregation propensity and cellular interactions[35].
The transition from functional monomer to pathological aggregate involves a dramatic structural rearrangement that represents a paradigm for protein misfolding diseases[36]. Understanding this conformational conversion is critical for developing therapeutic interventions that can prevent or reverse the aggregation process.
Monomeric State: Under physiological conditions, α-syn exists as a natively unfolded monomer in equilibrium with helical membrane-bound states[37]. This conformational flexibility allows the protein to interact with multiple partners and respond to cellular conditions[38]. The monomeric form is characterized by a lack of well-defined tertiary structure, similar to other natively unfolded proteins, which enables it to adopt different conformations depending on its environment[39]. Upon binding to lipid membranes, the N-terminal domain adopts an α-helical conformation while the C-terminal region remains disordered[40].
Oligomeric Transition: In disease states, α-syn undergoes a structural transition from α-helical or disordered states to β-sheet-rich conformations[41]. This conversion is facilitated by multiple factors:
Fibril Formation: β-sheet-rich oligomers seed the formation of insoluble amyloid fibrils[47]. These fibrils have a characteristic cross-β structure and can template the conversion of additional α-syn molecules, enabling prion-like propagation[48]. The fibrils formed in different synucleinopathies have distinct structural features, giving rise to the concept of "strains" that may determine clinical phenotype[49].
Pathological α-syn can spread between cells through prion-like mechanisms that represent a fundamental shift in our understanding of neurodegenerative disease progression[50]:
Intercellular Transmission: Misfolded α-syn can be released from neurons through various mechanisms including exocytosis, exosome release, and membrane permeabilization[51]. These extracellular species can be taken up by neighboring neurons through endocytosis, establishing a template for further aggregation[52]. The release of α-syn may be increased under conditions of cellular stress, and extracellular α-syn can activate inflammatory responses in microglia and astrocytes[53].
Strain Diversity: α-syn aggregates exist as distinct "strains" with different structural properties and biological activities[54]. These strains may underlie the clinical heterogeneity of synucleinopathies, with different fibril structures producing different disease phenotypes[55]. Importantly, these strains can be transmitted between individuals in experimental settings, supporting the prion-like nature of α-syn propagation[56]. The structural diversity of α-syn strains is analogous to the strain diversity observed in prion diseases, where different conformations of the same protein produce distinct clinical phenotypes[57].
Neural Circuit Spread: The progression of α-syn pathology in PD follows specific neural circuits, as described in the Braak staging system[58]. This pattern suggests that pathology spreads along anatomically connected regions, potentially through trans-synaptic transmission[59]. The selective vulnerability of specific neuronal populations may relate to their connectivity, metabolic demands, or intrinsic properties that make them more susceptible to α-syn propagation[60].
α-Syn aggregation leads to neuronal dysfunction through multiple mechanisms that contribute to the progressive neurodegeneration observed in synucleinopathies[61]:
Loss of Normal Function: Aggregated α-syn loses its physiological functions, disrupting synaptic vesicle regulation, dopamine metabolism, and cellular homeostasis[62]. The sequestration of α-syn into inclusions removes the functional protein from its normal cellular locations, creating a deficiency that contributes to synaptic dysfunction.
Gain of Toxic Function: Pathological α-syn species acquire novel toxic properties that actively contribute to neurodegeneration[63]:
Lewy bodies and Lewy neurites are the characteristic histopathological inclusions in PD and DLB, representing the morphological hallmark of α-syn pathology[69]:
Lewy Bodies: These spherical inclusions are primarily composed of phosphorylated, ubiquitinated α-syn fibrils embedded in a dense network of neurofilament proteins[70]. Detailed biochemical analysis has revealed that Lewy bodies contain:
The architecture of Lewy bodies shows a dense core surrounded by a less dense halo, although this classic morphology is not always apparent and may reflect the stage of inclusion formation[^77].
Lewy Neurites: These are abnormal neuritic processes containing α-syn inclusions, often appearing as twisted or dystrophic profiles when visualized with silver stains or immunohistochemistry[^78]. They represent early pathological changes that frequently precede Lewy body formation and are abundant in regions affected early in disease, including the dorsal motor nucleus and olfactory bulb[^79].
α-Syn in inclusions is extensively modified, with these modifications serving as both pathological markers and potential contributors to disease progression[^80]:
Serine 129 Phosphorylation: Approximately 90% of α-syn in Lewy bodies is phosphorylated at Ser129, in contrast to the minimal phosphorylation observed in normal brain[^81]. This modification promotes fibril formation in vitro and is a specific marker for pathological α-syn[^82]. Phospho-Ser129 antibodies are widely used diagnostically to detect Lewy pathology in research and clinical settings, enabling sensitive detection that surpasses traditional histological methods[^83].
Other Post-Translational Modifications observed in Lewy bodies include[^84]:
α-Syn pathology in PD shows characteristic patterns of progression that have been extensively documented and correlate with clinical features[^90]:
Braak Staging: The progression of Lewy pathology follows a predictable pattern that reflects the spread of pathology through connected neural circuits[^91]:
Clinical Correlations: The spread of pathology correlates with clinical features in a generally predictable manner[^92]:
However, it is important to note that the Braak staging model has limitations and does not account for all patterns of disease progression observed clinically[^93].
DLB shows more extensive cortical involvement than PD, representing a distinct clinical and pathological entity within the synucleinopathy spectrum[^94]:
Pathological Features[^95]:
Clinical Features include[^96]:
The overlap between DLB and Parkinson's disease with dementia (PDD) is substantial, with both conditions characterized by Lewy body pathology and cognitive decline. The distinction between these entities is based on the temporal relationship between motor symptoms and cognitive decline, with DLB defined by cognitive symptoms appearing before or within one year of motor symptoms[^97].
MSA represents a distinct pattern of α-syn pathology with fundamental differences from PD and DLB[^98]:
Glial Cytoplasmic Inclusions: Unlike PD and DLB, MSA features α-syn inclusions primarily in oligodendrocytes rather than neurons[^99]. These glial cytoplasmic inclusions (GCIs) are the hallmark pathological feature of MSA and are composed of filamentous α-syn that is extensively phosphorylated at Ser129[^100]. The mechanism by which α-syn accumulates in oligodendrocytes remains incompletely understood but may involve uptake from neurons or impaired protein clearance in these cells[^101].
Clinical Phenotype[^102]:
The distinction between MSA and PD has important prognostic and therapeutic implications, as the response to dopaminergic medications is markedly different between these conditions[^103].
Active and passive immunization strategies targeting α-syn aggregation represent one of the most advanced therapeutic approaches to disease modification in synucleinopathies[^104]:
Passive Immunization involves administration of antibodies that target α-syn and promote its clearance:
Active Immunization aims to stimulate the patient's own immune system to produce anti-α-syn antibodies:
The challenges facing immunotherapy approaches include the blood-brain barrier penetration, the need for early intervention before significant neuronal loss, and the potential for immunological complications[^111].
Aggregation Inhibitors aim to prevent the formation or promote the clearance of toxic α-syn species:
Targeting Signaling Pathways[^116]:
RNA Interference strategies aim to reduce the production of α-syn:
Gene Editing approaches offer the potential for precise genetic intervention:
Beyond directly targeting α-syn, several strategies aim to protect neurons from α-syn-induced toxicity:
CSF analysis provides insights into α-syn pathology and is increasingly used in clinical diagnosis and research[^126]:
Core Biomarkers[^127]:
Emerging Biomarkers[^132]:
PET Ligands: Several radiotracers are in development for imaging α-syn[^136]:
Other Techniques[^140]:
Several SNCA mutations cause autosomal dominant PD, providing crucial insights into disease mechanisms[^144]:
| Mutation | Effect | Clinical Features |
|---|---|---|
| A53T (Ala53Thr) | Accelerated aggregation | Early onset (mean 46 years), rapid progression, often with dementia |
| A30P (Ala30Pro) | Reduced membrane binding | Classic PD phenotype, variable onset |
| E46K (Glu46Lys) | Enhanced aggregation | PD with dementia, early cognitive impairment |
| H50Q (His50Gln) | Altered aggregation | Variable phenotype, often late onset |
| G51D (Gly51Asp) | Intermediate aggregation | Early onset, atypical features including rapid progression |
| A53E | Increased aggregation | Similar to A53T with additional cerebellar features |
Gene Multiplications: Duplications and triplications of the SNCA gene cause autosomal dominant PD with variable penetrance[^145]. The phenotype correlates with gene dosage, with triplications causing earlier onset and more severe disease[^146].
SNCA Rep1 Polymorphism: A variable repeat in the SNCA promoter affects gene expression, with longer repeats associated with increased risk[^147]. This polymorphism may account for up to 3% of Parkinson's disease risk in sporadic cases[^148].
Copy Number Variants: SNCA multiplications cause PD with dementia, demonstrating that increased expression of wild-type α-syn is sufficient to cause disease[^149].
Linkage with Other Genes[^150]:
The development of disease-modifying therapies targeting α-synuclein has accelerated significantly in recent years, representing a major focus of translational neuroscience[59:1]. Several therapeutic modalities have advanced from preclinical development to clinical testing, with varying degrees of success:
Immunotherapy Approaches: Both passive and active immunization strategies have progressed to clinical trials, with the goal of promoting clearance of pathological α-synuclein[60:1]. Passive antibodies such as prasinezumab have shown signals of efficacy in slowing motor progression, while active vaccines like UB-312 aim to induce endogenous antibody production. The challenge of blood-brain barrier penetration remains a significant hurdle, with novel antibody formats and delivery strategies under investigation.
Small Molecule Modulators: Aggregation inhibitors such as anle138b target the formation of toxic oligomeric species, while repositioned drugs like nilotinib (a c-Abl inhibitor) have shown promise in clinical trials[61:1]. The complexity of α-synuclein biology and the multiple pathways involved suggest that combination therapies may be necessary for optimal disease modification.
Gene Therapy and RNA-Based Approaches: Direct targeting of SNCA expression through RNA interference or gene editing represents a more fundamental approach to reducing the pathological protein burden[62:1]. AAV-delivered shRNA constructs have shown promise in preclinical models, and clinical translation is underway.
The development of biomarkers for synucleinopathies has advanced substantially, enabling earlier diagnosis and better patient selection for clinical trials[63:1]:
Seed-Amplification Assays: RT-QuIC and related seed-amplification technologies can detect pathological α-synuclein in CSF with high sensitivity (>90%) and specificity[64:1]. These assays represent a major advance in biomarker development and are now being implemented in clinical practice and clinical trials for patient stratification.
Blood-Based Biomarkers: Emerging blood-based markers, including phosphorylated α-synuclein and neurofilament light chain (NfL), offer less invasive alternatives to lumbar puncture[65:1]. These markers show promise for disease progression monitoring and treatment response assessment.
Neuroimaging Markers: While no α-synuclein-specific PET ligand is yet approved, advances in multimodal imaging combining dopamine transporter imaging, structural MRI, and novel tracers improve diagnostic accuracy and monitoring capabilities[66:1].
The clinical trial landscape for synucleinopathies has expanded considerably, with numerous Phase 2 and 3 trials ongoing or recently completed[67:1]:
| Agent | Mechanism | Phase | Status | Key Outcomes |
|---|---|---|---|---|
| Prasinezumab | Anti-α-syn Ab | 2 | Complete | Slowed motor progression in early PD |
| Cinpanemab | Anti-α-syn Ab | 2 | Complete | Primary endpoints not met |
| Anle138b | Aggregation inhibitor | 1/2 | Ongoing | Safety and efficacy in MSA/PD |
| Nilotinib | c-Abl inhibitor | 2 | Complete | Mixed results; signal in exploratory endpoints |
| UB-312 | α-syn vaccine | 1 | Ongoing | Safety and immunogenicity |
| NLY01 | GLP-1 RA | 2 | Recruiting | Anti-inflammatory and neuroprotective |
Trial Design Considerations: Key challenges include identifying appropriate patient populations (early vs. established disease), selecting sensitive outcome measures, and establishing biomarker correlates of treatment response. The field has moved toward enrichment strategies using biomarker confirmation in recent trials.
The burden of synucleinopathies extends beyond the individual patient to caregivers and healthcare systems[68:1]:
Quality of Life: Patients with PD and related disorders experience significant impacts on daily functioning, social participation, and psychological well-being. Non-motor symptoms, including autonomic dysfunction, sleep disorders, and cognitive impairment, often have greater impact on quality of life than motor symptoms.
Caregiver Burden: Family caregivers of patients with advanced synucleinopathies experience high rates of burnout, depression, and financial stress. The progressive nature of these disorders, with motor and cognitive decline over years to decades, creates sustained demands on caregiver resources.
Healthcare Utilization: Synucleinopathies are associated with substantial healthcare costs, including medication management, physical and occupational therapy, and institutionalization in advanced stages. Disease-modifying therapies, if successful, could reduce long-term healthcare burden.
Despite significant progress, multiple challenges remain in developing effective therapies[69:1]:
Blood-Brain Barrier Delivery: The majority of biological therapeutics cannot penetrate the brain adequately, limiting the efficacy of antibodies and large molecules. Novel delivery strategies, including focused ultrasound and receptor-mediated transport, are under investigation.
Treatment Window: Neurodegeneration is largely irreversible by the time clinical symptoms appear. Identifying at-risk individuals and initiating therapy before substantial neuronal loss remains a critical challenge. Prodromal markers, including REM sleep behavior disorder and hyposmia, offer opportunities for early intervention.
Disease Heterogeneity: Synucleinopathies encompass multiple distinct clinical entities (PD, DLB, MSA) with potentially different underlying pathologies. Personalized approaches based on biomarker profiles may be necessary.
Biomarker Validation: While seed-amplification assays show promise, standardization across laboratories and validation in diverse populations are needed before widespread clinical implementation.
The therapeutic landscape for synucleinopathies continues to evolve, with several promising approaches on the horizon[70:1]:
Combination Therapies: Targeting multiple pathways simultaneously—aggregation, propagation, neuroinflammation, and neuroprotection—may provide synergistic benefits.
Cellular Replacement: Stem cell-derived dopaminergic neurons and their transplantation into the brain represent a potential restorative approach. Early-phase clinical trials are investigating the safety and efficacy of this strategy.
Precision Medicine Approaches: Genetic stratification based on SNCA mutations, GBA status, and other risk factors may enable more targeted therapeutic development.
Prevention in At-Risk Populations: Identifying individuals through genetic testing and prodromal markers offers the possibility of preventive intervention before symptomatic disease develops.
The integration of biomarker-driven patient selection, sensitive clinical endpoints, and mechanism-focused interventions offers the best path forward for developing effective disease-modifying treatments for synucleinopathies.
Alpha-synuclein pathology represents a central mechanism in neurodegenerative disease, linking genetic, molecular, and clinical aspects of synucleinopathies. Understanding the transformation from functional protein to toxic aggregate, and the mechanisms by which pathology spreads through the nervous system, provides critical insights for therapeutic development. The past two decades have witnessed remarkable progress in our understanding of α-syn biology, from the identification of pathogenic mutations to the characterization of distinct strains and propagation mechanisms.
Current approaches targeting α-syn through immunotherapies, small molecule inhibitors, and gene-based strategies offer genuine hope for disease-modifying treatments. The advancement of biomarkers, including seed-amplification assays and neuroimaging ligands, enables earlier diagnosis and better patient selection for clinical trials. As these approaches continue to mature, the potential for preventive interventions in at-risk individuals becomes increasingly tangible.
The heterogeneity of synucleinopathies, with distinct clinical presentations ranging from classic PD to MSA and DLB, highlights the complexity of α-syn pathology and the need for personalized therapeutic approaches. Future research must address the challenges of blood-brain barrier penetration, biomarker validation, and identification of optimal treatment windows before irreversible neuronal loss occurs. The integration of genetic, clinical, and biomarker data will be essential for developing effective therapies that can halt or reverse the progression of these devastating disorders.
Spillantini MG, Goedert M. 'The α-synucleinopathies: Parkinson''s disease, dementia with Lewy bodies, and multiple system atrophy'. 2000. ↩︎
McKeith IG, et al. 'Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium'. 2017. ↩︎
Poewe W, et al. Parkinson disease. 2017. ↩︎
Lewy FH. Paralysis agitans. 1912. ↩︎
Spillantini MG, et al. α-Synuclein in Lewy bodies. 1997. ↩︎
Polymeropoulos MH, et al. Mutation in the α-synuclein gene identified in families with Parkinson's disease. 1997. ↩︎
Bendor JT, Logan TP, Edwards RH. The function of α-synuclein. 2013. ↩︎
Iwai A, et al. The precursor protein of non-Aβ component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. 1995. ↩︎
Murphy DD, Rueter SM, Trojanowski JQ, Lee VM. Synucleins are developmentally expressed, and α-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. 2000. ↩︎
Cabin DE, et al. Synaptic vesicle depletion in mice lacking α-synuclein. 2002. ↩︎
Busch DJ, et al. Acute increase of α-synuclein inhibits synaptic vesicle recycling. 2014. ↩︎
Vargas KJ, et al. Synucleins may regulate the size of the vesicle pool in presynaptic terminals. 2014. ↩︎
Greten-Harrison B, et al. αβγ-Synuclein triple knockout mice reveal age-dependent neuronal dysfunction. 2010. ↩︎
Tehrani R, Khodadad M, Bahramy E. The role of α-synuclein in dopamine metabolism and Parkinson's disease. 2022. ↩︎
Peng X, et al. α-Synuclein regulates tyrosine hydroxylase gene expression. 2005. ↩︎
Guigoni C, et al. Role of vesicular monoamine transporter, but not of dopamine transporter, in motor dysfunction induced by chronic inhibition of brain dopamine synthesis. 2005. ↩︎
Wong YC, Krainc D. 'α-Synuclein toxicity in neurodegeneration: Mechanism and therapeutic strategies'. 2017. ↩︎
Cooper AA, et al. α-Synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. 2006. ↩︎
Liu G, et al. α-Synuclein is specifically expressed in mitochondria subject to oxidative stress. 2009. ↩︎
Cuervo AM, et al. Impaired degradation of mutant α-synuclein by chaperone-mediated autophagy. 2004. ↩︎
Danzer KM, et al. Different species of α-synuclein oligomers induce calcium influx and seeding. 2007. ↩︎
Sharon R, et al. α-Synuclein is localized to the nucleus and its expression is altered in a cellular model of oxidative stress. 2001. ↩︎
Kim TD, et al. Regional expression of the amyloid-β protein precursor and α-synuclein in the mouse brain. 2000. ↩︎
Fan Y, et al. Interplay between α-synuclein and other proteins in neurodegenerative disease. 2021. ↩︎
Clayton DF, George JM. Synucleins in synaptic plasticity and neurodegenerative disorders. 1999. ↩︎
Davidson WS, et al. Stabilization of α-synuclein secondary structure upon binding to synthetic membranes. 1998. ↩︎
Li J, Uversky VN, Fink AL. Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human α-synuclein. 2001. ↩︎
Jensen PH, et al. α-Synuclein binds to the nuclear membrane and regulates gene expression. 2008. ↩︎
Uéda K, et al. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. 1993. ↩︎
Giasson BI, et al. A structural and functional role for 11-mer repeats in α-synuclein. 2003. ↩︎
Hashimoto M, et al. Human recombinant NACP/α-synuclein is aggregated and cytotoxic. 1998. ↩︎
Jakes R, Spillantini MG, Goedert M. Identification of two distinct synucleins from human brain. 1994. ↩︎
Nielsen MS, et al. α-Synuclein interacts with the C-terminal domain of the amyloid precursor protein. 2001. ↩︎
Hoyer W, et al. Dependence of α-synuclein aggregate morphology on solution conditions. 2002. ↩︎
Oueslati A, Ximerakis M, Vekrellis K. Protein phosphorylation, aggregation, and transformation in Parkinson's disease. 2014. ↩︎
Fink AL. The aggregation and fibrillation of α-synuclein. 2006. ↩︎
Weinreb PH, et al. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. 1996. ↩︎
Uversky VN, et al. Structure and dynamics of the human α-synuclein. 2001. ↩︎
Dyson HJ, Wright PE. Intrinsically unstructured proteins and their functions. 2005. ↩︎
Jao CC, et al. Structure of membrane-bound α-synuclein from site-directed spin labeling and computational refinement. 2008. ↩︎
Conway KA, et al. Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to familial Parkinson's disease. 2000. ↩︎
Tenreiro S, et al. Phosphorylation of α-synuclein is an early event in the disease process. 2014. ↩︎
Bin Y, et al. The role of metal ions in the pathogenesis of Parkinson's disease. 2021. ↩︎
Zhou Z, et al. Membrane damage promotes amyloid aggregation of α-synuclein. 2008. ↩︎
Singleton AB, et al. α-Synuclein locus triplication causes Parkinson's disease. 2003. ↩︎
Cookson MR. α-Synuclein and neuronal cell death. 2009. ↩︎
Serpell LC, Berriman J, Jakes R, Goedert M, Crowther RA. Fiber diffraction of synthetic α-synuclein filaments shows amyloid-like cross-β conformation. 2000. ↩︎
Prusiner SB, et al. Evidence for α-synuclein prions causing multiple system atrophy in humans with parkinsonism. 2015. ↩︎
Gu远 Y, et al. α-Synuclein strains from Parkinson's disease and multiple systemopathy patients encode distinct protein conformations. 2020. ↩︎
Brundin P, Melki R. Prying into the prion hypothesis of Parkinson's disease. 2017. ↩︎
Lee HJ, et al. Assembly-dependent endocytosis and clearance of extracellular α-synuclein. 2008. ↩︎
Deshmane SL, et al. Extracellular α-synuclein enters dopaminergic cells by modulating flotillin-1/2-mediated endocytosis. 2009. ↩︎
Lee HJ, et al. Autophagic failure promotes the exocytosis and intercellular transfer of α-synuclein. 2013. ↩︎
Lau A, et al. α-Synuclein strains from Parkinson's disease and multiple system atrophy patients exhibit distinct conformational and functional properties. 2020. ↩︎
Peelaerts W, et al. α-Synuclein strains cause distinct synucleinopathies after local and systemic administration. 2015. ↩︎
Woerman AL, et al. Propagation of prions causing synucleinopathies in cultured cells. 2015. ↩︎
Braak H, et al. Braak H, et al. St. ↩︎
Poewe W, et al. Disease-modifying approaches for Parkinson's disease. 2020. ↩︎ ↩︎
Schenk DB, et al. 'Efficacy and safety of prasinezumab in early Parkinson''s disease: PASADENA Phase 2 trial'. 2021. ↩︎ ↩︎
Hebron ML, et al. 'Repurposing nilotinib: c-Abl inhibition for the treatment of Parkinson''s disease'. 2020. ↩︎ ↩︎
Jassen A, et al. AAV-mediated alpha-synuclein RNAi reduces neurodegeneration and ameliorates behavior in a PD model. 2023. ↩︎ ↩︎
St真fed CA, et al. Alpha-synuclein seed amplification assay for diagnosis and biomarker research in synucleinopathies. 2024. ↩︎ ↩︎
Fairfoul G, et al. Alpha-synuclein RT-QuIC in cerebrospinal fluid of synucleinopathies. 2016. ↩︎ ↩︎
Hansson O, et al. Blood-based biomarkers for Parkinson's disease. 2022. ↩︎ ↩︎
McGhee DJ, et al. 'Neuroimaging in Parkinson''s disease: Recent advances and future directions'. 2023. ↩︎ ↩︎
Sardi SP, et al. 'Clinical trials in synucleinopathies: Current status and future directions'. 2024. ↩︎ ↩︎
Hely MA, et al. The burden of Parkinson's disease on caregivers and families. 2023. ↩︎ ↩︎
Kalia LV, Lang AE. Parkinson's disease. 2015. ↩︎ ↩︎
Jankovic J, et al. 'Parkinson disease: New insights into pathophysiology and treatment'. 2024. ↩︎ ↩︎